Skip to main content

Advertisement

SpringerLink
Log in

Therapeutic potential of erythropoietin in cardiovascular disease: Erythropoiesis and beyond

  • Published:
Current Heart Failure Reports Aims and scope Submit manuscript

Abstract

Erythropoietin (EPO) is a glycoprotein hormone implicated in the regulation of red blood cell production. Anemia is common in chronic heart failure (CHF) patients and associated with an inappropriately low EPO-production, suggesting a role for its recombinant human form (rhEPO) in treatment. Although safety concerns have been raised regarding treatment with rhEPO in patients with chronic kidney disease, treatment with rhEPO in patients with CHF has so far been safe and well tolerated. The effect of rhEPO on outcome in anemic CHF patients is under investigation in a phase III clinical trial. In addition to its erythropoietic effects, EPO has been detected in the cardiovascular system, fueling intense research into possible non-hematopoietic effects. EPO has been shown to exert protective effects on the heart during acute myocardial ischemia and improve cardiac function in experimental CHF. Acute protection is mediated through reduction of apoptotic cell death. Improvement of cardiac function in CHF is related to myocardial neovascularization. EPO exhibits a vast array of beneficial effects in cardiovascular disease. In addition to the correction of anemia in CHF, rhEPO might benefit patients with cardiovascular disease.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Fandrey J: Oxygen-dependent and tissue-specific regulation of erythropoietin gene expression. Am J Physiol Regul Integr Comp Physiol 2004, 286:R977–R988.

    PubMed  CAS  Google Scholar 

  2. Sato T, Maekawa T, Watanabe S, et al.: Erythroid progenitors differentiate and mature in response to endogenous erythropoietin. J Clin Invest 2000, 106:263–270.

    Article  PubMed  CAS  Google Scholar 

  3. Tang YD, Katz SD: Anemia in chronic heart failure: prevalence, etiology, clinical correlates, and treatment options. Circulation 2006, 113:2454–2461.

    Article  PubMed  Google Scholar 

  4. van der Meer P, Voors AA, Lipsic E, et al.: Erythropoietin in cardiovascular diseases. Eur Heart J 2004, 25:285–291.

    Article  PubMed  CAS  Google Scholar 

  5. van der Meer P, Voors AA, Lipsic E, et al.: Prognostic value of plasma erythropoietin on mortality in patients with chronic heart failure. J Am Coll Cardiol 2004, 44:63–67.

    Article  PubMed  CAS  Google Scholar 

  6. Westenbrink BD, Visser FW, Voors AA, et al.: Anaemia in chronic heart failure is not only related to impaired renal perfusion and blunted erythropoietin production, but to fluid retention as well. Eur Heart J 2007, 28:166–171.

    Article  PubMed  CAS  Google Scholar 

  7. Opasich C, Cazzola M, Scelsi L, et al.: Blunted erythropoietin production and defective iron supply for erythropoiesis as major causes of anaemia in patients with chronic heart failure. Eur Heart J 2005, 26:2232–2237.

    Article  PubMed  CAS  Google Scholar 

  8. Iversen PO, Woldbaek PR, Tonnessen T, et al.: Decreased hematopoiesis in bone marrow of mice with congestive heart failure. Am J Physiol Regul Integr Comp Physiol 2002, 282:R166–R172.

    PubMed  CAS  Google Scholar 

  9. Weiss G, Goodnough LT: Anemia of chronic disease. N Engl J Med 2005, 352:1011–1023.

    Article  PubMed  CAS  Google Scholar 

  10. Ferrucci L, Guralnik JM, Woodman RC, et al.: Proinflammatory state and circulating erythropoietin in persons with and without anemia. Am J Med 2005, 118:1288.

    Article  PubMed  Google Scholar 

  11. van der Meer P, Lipsic E, Westenbrink BD, et al.: Levels of hematopoiesis inhibitor N-acetyl-seryl-aspartyl-lysyl-proline partially explain the occurrence of anemia in heart failure. Circulation 2005, 112:1743–1747.

    Article  PubMed  CAS  Google Scholar 

  12. Nanas JN, Matsouka C, Karageorgopoulos D, et al.: Etiology of anemia in patients with advanced heart failure. J Am Coll Cardiol 2006, 48:2485–2489.

    Article  PubMed  Google Scholar 

  13. Westenbrink BD, Voors AA, van Veldhuisen DJ: Is anemia in chronic heart failure caused by iron deficiency? J Am Coll Cardiol 2007, 49:2302.

    Article  Google Scholar 

  14. Tan CC, Eckardt KU, Firth JD, et al.: Feedback modulation of renal and hepatic erythropoietin mRNA in response to graded anemia and hypoxia. Am J Physiol 1992, 263:F474–F481.

    PubMed  CAS  Google Scholar 

  15. Maiese K, Li F, Chong ZZ: New avenues of exploration for erythropoietin. JAMA 2005, 293:90–95.

    Article  PubMed  CAS  Google Scholar 

  16. Brines M, Cerami A: Emerging biological roles for erythropoietin in the nervous system. Nat Rev Neurosci 2005, 6:484–494.

    Article  PubMed  CAS  Google Scholar 

  17. Beleslin-Cokic BB, Cokic VP, Yu X, et al.: Erythropoietin and hypoxia stimulate erythropoietin receptor and nitric oxide production by endothelial cells. Blood 2004, 104:2073–2080.

    Article  PubMed  CAS  Google Scholar 

  18. Wu H, Lee SH, Gao J, et al.: Inactivation of erythropoietin leads to defects in cardiac morphogenesis. Development 1999, 126:3597–3605.

    PubMed  CAS  Google Scholar 

  19. Suzuki N, Ohneda O, Takahashi S, et al.: Erythroid-specific expression of the erythropoietin receptor rescued its null mutant mice from lethality. Blood 2002, 100:2279–2288.

    Article  PubMed  CAS  Google Scholar 

  20. Tada H, Kagaya Y, Takeda M, et al.: Endogenous erythropoietin system in non-hematopoietic lineage cells plays a protective role in myocardial ischemia/reperfusion. Cardiovasc Res 2006, 71:466–477.

    Article  PubMed  CAS  Google Scholar 

  21. Nakano M, Satoh K, Fukumoto Y, et al.: Important role of erythropoietin receptor to promote VEGF expression and angiogenesis in peripheral ischemia in mice. Circ Res 2007, 100:662–669.

    Article  PubMed  CAS  Google Scholar 

  22. Asaumi Y, Kagaya Y, Takeda M, et al.: Protective role of endogenous erythropoietin system in nonhematopoietic cells against pressure overload-induced left ventricular dysfunction in mice. Circulation 2007, 115:2022–2032.

    Article  PubMed  CAS  Google Scholar 

  23. Satoh K, Kagaya Y, Nakano M, et al.: Important role of endogenous erythropoietin system in recruitment of endothelial progenitor cells in hypoxia-induced pulmonary hypertension in mice. Circulation 2006, 113:1442–1450.

    Article  PubMed  CAS  Google Scholar 

  24. Namiuchi S, Kagaya Y, Ohta J, et al.: High serum erythropietin level is associated with smaller infarct size in patients with acute myocardial infarction who undergo successful primary percutaneous coronary intervention. J Am Coll Cardiol 2005, 45:1406–1412.

    Article  PubMed  CAS  Google Scholar 

  25. Ferrario M, Massa M, Rosti V, et al.: Early haemoglobin-independent increase of plasma erythropoietin levels in patients with acute myocardial infarction. Eur Heart J 2007, [Epub ahead of print].

  26. Rui T, Feng Q, Lei M, et al.: Erythropoietin prevents the acute myocardial inflammatory response induced by ischemia/reperfusion via induction of AP-1. Cardiovasc Res 2005, 65:719–727.

    Article  PubMed  CAS  Google Scholar 

  27. Burger D, Lei M, Geoghegan-Morphet N, et al.: Erythropoietin protects cardiomyocytes from apoptosis via up-regulation of endothelial nitric oxide synthase. Cardiovasc Res 2006, 72:51–59.

    Article  PubMed  CAS  Google Scholar 

  28. Calvillo L, Latini R, Kajstura J, et al.: Recombinant human erythropoietin protects the myocardium from ischemia-reperfusion injury and promotes beneficial remodeling. Proc Natl Acad Sci U S A 2003, 100:4802–4806.

    Article  PubMed  CAS  Google Scholar 

  29. Lipsic E, Schoemaker RG, van der Meer P, et al.: Protective effects of erythropoietin in cardiac ischemia: from bench to bedside. J Am Coll Cardiol 2006, 48:2161–2167.

    Article  PubMed  CAS  Google Scholar 

  30. Lipsic E, van der Meer P, Henning RH, et al.: Timing of erythropoietin treatment for cardioprotection in ischemia/reperfusion. J Cardiovasc Pharmacol 2004, 44:473–479.

    Article  PubMed  CAS  Google Scholar 

  31. van der Meer P, Lipsic E, Henning RH, et al.: Erythropoietin induces neovascularization and improves cardiac function in rats with heart failure after myocardial infarction. J Am Coll Cardiol 2005, 46:125–133.

    Article  PubMed  CAS  Google Scholar 

  32. Kalkman EA, Bilgin YM, van Haren P, et al.: Determinants of coronary reserve in rats subjected to coronary artery ligation or aortic banding. Cardiovasc Res 1996, 32:1088–1095.

    Article  PubMed  CAS  Google Scholar 

  33. de Boer RA, Pinto YM, van Veldhuisen DJ: The imbalance between oxygen demand and supply as a potential mechanism in the pathophysiology of heart failure: the role of microvascular growth and abnormalities. Microcirculation 2003, 10:113–126.

    Article  PubMed  Google Scholar 

  34. Jaquet K, Krause K, Tawakol-Khodai M, et al.: Erythropoietin and VEGF exhibit equal angiogenic potential. Microvasc Res 2002, 64:326–333.

    Article  PubMed  CAS  Google Scholar 

  35. Ribatti D, Presta M, Vacca A, et al.: Human erythropoietin induces a pro-angiogenic phenotype in cultured endothelial cells and stimulates neovascularization in vivo. Blood 1999, 93:2627–2636.

    PubMed  CAS  Google Scholar 

  36. Ribatti D, Vacca A, Roccaro AM, et al.: Erythropoietin as an angiogenic factor. Eur J Clin Invest 2003, 33:891–896.

    Article  PubMed  CAS  Google Scholar 

  37. Bahlmann FH, de Groot K, Spandau JM, et al.: Erythropoietin regulates endothelial progenitor cells. Blood 2004, 103:921–926.

    Article  PubMed  CAS  Google Scholar 

  38. George J, Goldstein E, Abashidze A, et al.: Erythropoietin promotes endothelial progenitor cell proliferative and adhesive properties in a PI 3-kinase-dependent manner. Cardiovasc Res 2005, 68:299–306.

    Article  PubMed  CAS  Google Scholar 

  39. Heeschen C, Aicher A, Lehmann R, et al.: Erythropoietin is a potent physiologic stimulus for endothelial progenitor cell mobilization. Blood 2003, 102:1340–1346.

    Article  PubMed  CAS  Google Scholar 

  40. Asahara T, Murohara T, Sullivan A, et al.: Isolation of putative progenitor endothelial cells for angiogenesis. Science 1997, 275:964–967.

    Article  PubMed  CAS  Google Scholar 

  41. Hirata A, Minamino T, Asanuma H, et al.: Erythropoietin enhances neovascularization of ischemic myocardium and improves left ventricular dysfunction after myocardial infarction in dogs. J Am Coll Cardiol 2006, 48:176–184.

    Article  PubMed  CAS  Google Scholar 

  42. Li Y, Takemura G, Okada H, et al.: Reduction of inflammatory cytokine expression and oxidative damage by erythropoietin in chronic heart failure. Cardiovasc Res 2006, 71:684–694.

    Article  PubMed  CAS  Google Scholar 

  43. Prunier F, Pfister O, Hadri L, et al.: Delayed erythropoietin therapy reduces post-MI cardiac remodeling only at a dose that mobilizes endothelial progenitor cells. Am J Physiol Heart Circ Physiol 2007, 292:H522–H529.

    Article  PubMed  CAS  Google Scholar 

  44. Hamed S, Barshack I, Luboshits G, et al.: Erythropoietin improves myocardial performance in doxorubicin-induced cardiomyopathy. Eur Heart J 2006, 27:1876–1883.

    Article  PubMed  CAS  Google Scholar 

  45. Li L, Takemura G, Li Y, et al.: Preventive effect of erythropoietin on cardiac dysfunction in doxorubicin-induced cardiomyopathy. Circulation 2006, 113:535–543.

    Article  PubMed  CAS  Google Scholar 

  46. Westenbrink BD, Lipsic E, van der Meer P, et al.: Erythropoietin improves cardiac function through endothelial progenitor cell and vascular endothelial growth factor mediated neovascularization. Eur Heart J 2007, [Epub ahead of print].

  47. Besarab A, Bolton WK, Browne JK, et al.: The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med 1998, 339:584–590.

    Article  PubMed  CAS  Google Scholar 

  48. Leist M, Ghezzi P, Grasso G, et al.: Derivatives of erythropoietin that are tissue protective but not erythropoietic. Science 2004, 305:239–242.

    Article  PubMed  CAS  Google Scholar 

  49. Brines M, Grasso G, Fiordaliso F, et al.: Erythropoietin mediates tissue protection through an erythropoietin and common beta-subunit heteroreceptor. Proc Natl Acad Sci U S A 2004, 101:14907–14912.

    Article  PubMed  CAS  Google Scholar 

  50. Fiordaliso F, Chimenti S, Staszewsky L, et al.: A non-erythropoietic derivative of erythropoietin protects the myocardium from ischemia-reperfusion injury. Proc Natl Acad Sci U S A 2005, 102:2046–2051.

    Article  PubMed  CAS  Google Scholar 

  51. Moon C, Krawczyk M, Paik D, et al.: Erythropoietin, modified to not stimulate red blood cell production, retains its cardioprotective properties. J Pharmacol Exp Ther 2006, 316:999–1005.

    Article  PubMed  CAS  Google Scholar 

  52. Silverberg DS, Wexler D, Sheps D, et al.: The effect of correction of mild anemia in severe, resistant congestive heart failure using subcutaneous erythropoietin and intravenous iron: a randomized controlled study. J Am Coll Cardiol 2001, 37:1775–1780.

    Article  PubMed  CAS  Google Scholar 

  53. van Veldhuisen DJ, McMurray JJ: Are erythropoietin stimulating proteins safe and efficacious in heart failure? Why we need an adequately powered randomised outcome trial. Eur J Heart Fail 2007, 9:110–112.

    Article  PubMed  CAS  Google Scholar 

  54. Singh AK, Szczech L, Tang KL, et al.: Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med 2006, 355:2085–2098.

    Article  PubMed  CAS  Google Scholar 

  55. Lipsic E, van der Meer P, Voors AA, et al.: A single bolus of a long-acting erythropoietin analogue darbepoetin alfa in patients with acute myocardial infarction: a randomized feasibility and safety study. Cardiovasc Drugs Ther 2006, 20:135–141.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. University Medical Center Groningen, Hanzeplein 1, P.O. Box 30001, 9700 RB, Groningen, The Netherlands

    B. Daan Westenbrink

Authors
  1. B. Daan Westenbrink
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Adriaan A. Voors
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Willem-Peter T. Ruifrok
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Wiek H. van Gilst
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Dirk J. van Veldhuisen
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to B. Daan Westenbrink.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Westenbrink, B.D., Voors, A.A., Ruifrok, WP.T. et al. Therapeutic potential of erythropoietin in cardiovascular disease: Erythropoiesis and beyond. Curr Heart Fail Rep 4, 127–133 (2007). https://doi.org/10.1007/s11897-007-0030-5

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11897-007-0030-5

Keywords

Search

Navigation